Abstract:Objective Prostaglandins (PGs) play a major role in maintaining patency of the ductal arteriosus (DA). Pulmonary 15-hydroxyprostaglandin dehydrogenase (PGDH), which is ecoded by the hydroxyprostaglandin dehydrogenase ( HPGD ) gene, is the primary enzyme responsible for PG breakdown. Animal studies have shown HPGD -knockout mice have significantly higher prostaglandin E2 levels and no ductal remodeling. Functional variants of the HPGD gene that alter PG breakdown have not been studied in preterm infants with patent ductus arteriosus (PDA). Study Design This was an observational cohort study including extreme low birth weight (ELBW) infants classified as having spontaneous, medical, or procedural (transcatheter or surgical ligation) closure of their DA. Urine prostaglandin E metabolite (PGEM) levels were measured in ELBW infants following ibuprofen treatment using competitive ELISA. HPGD genetic variants rs8752, rs2612656, and rs9312555 were analyzed. Kruskal–Wallis, Fisher's exact, chi square, logistic regression, and Wilcoxon signed-rank tests were used; p < 0.05 was considered significant. Results Infants in the procedural closure group had a younger gestational age (GA). The incidence of spontaneous closure or medical closure was higher compared to procedural closure in the presence of any minor allele of rs8752 (67 and 27%, respectively; p = 0.01), when adjusted for GA and gender. Haplotype analysis of three variants of HPGD revealed differences when comparing the spontaneous and medical closure group to the procedural group ( p < 0.05). Urinary PGEM levels dropped significantly in those ELBW infants who responded to ibuprofen ( p = 0.003) in contrast to those who did not respond ( p = 0.5). Conclusion There was a different genotype distribution for the rs8752 genetic variant of the HPGD gene—as it relates to the mode of treatment for ELBW infants with PDA. We speculate that medical management in the presence of this variant facilitated additional PG breakdown, significantly abrogating the need for procedural closure. Additionally, differences in genotype and haplotype distributions implicate a specific HPGD genetic foundation for DA closure in ELBW infants. Key Points PGs and their metabolism play a major role in PDA patency or closure. Genetic variants of the HPGD gene influence mode of treatment of PDA in ELBW infants. ELBW infants with PDA that responded to medical closure had significantly decreased urine PGEM levels. Substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data: H.J.S., P.K., V.T., and L.A.P. Drafting the article or revising it critically for important intellectual content: H.J.S. and L.A.P. Final approval of the version to be published: L.A.P. Received: 17 October 2023 Accepted: 02 May 2024 Article published online: 31 May 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

Long Term Prostaglandin-E Therapy in Neonates with Emphasis on Complications in the Long Bones

Prostaglandin E1 used as a pre-operative treatment for the neonates with transposition of great vessels with intact ventricular septum

Prolonged prostaglandin E1 therapy in a neonate with pulmonary atresia and ventricular septal defect and the development of antral foveolar hyperplasia and hypertrophic pyloric stenosis

Prostaglandin‐E1 infusion in persistent pulmonary hypertension of the newborn

Long-Term Prostaglandin E1 Infusion for Newborns with Critical Congenital Heart Disease

[Long-Term Prognosis of Neonates with Necrotizing Enterocolitis].

Treatment of Patent Ductus Arteriosus and Short-Term Outcomes among Extremely Preterm Infants: a Multicentre Cohort Study

Effect of Long-term Administration of Prostaglandin E1 on Morphologic Changes in Ductus Arteriosus

The Progress in the Treatment of Persistent Pulmonary Hypertension in Neonatal

Effect of prostaglandin-E1 treatment on pyloric wall thickness in newborns with ductal-dependent critical congenital heart diseases

Do Predictors Exist for a Successful Withdrawal of Preoperative Prostaglandin E1 from Neonates with d-Transposition of the Great Arteries and Intact Ventricular Septum?

Reappraisal of the Prostaglandin E1 Dose for Early Newborns with Patent Ductus Arteriosus-Dependent Pulmonary Circulation

Association Between Early Prostacyclin Therapy and Extracorporeal Life Support Use in Patients With Congenital Diaphragmatic Hernia

Effects of Prostaglandin E1 and Balloon Atrial Septostomy on Cerebral Blood Flow and Oxygenation in Newborns Diagnosed with Transposition of the Great Arteries

Management of Persistent Pulmonary Hypertension in Newborns with ECMO Support: a Single Center's Experience

Prostaglandin E1-induced urticaria with harlequin change in a neonate with transposition of great vessels: A case report

Prostacyclin Treatment for Persistent Pulmonary Hypertension of the Newborn

Low-dose prostaglandin E1 is safe and effective for critical congenital heart disease: is it time to revisit the dosing guidelines?

Predictors of high maintenance prostaglandin E1 doses in neonates with critical congenital heart disease-ductal-dependent pulmonary circulation during preoperative care

Genetic Foundation of Prostaglandin Metabolism Influences Patent Ductus Arteriosus Closure in Extremely Low Birth Weight Infants

Effects of Prostaglandin E_1 on Hyperoxia Induced Lung Injury in Neonatal Rats